Therapeutic application of regeneration-associated cells: a novel

Chronic diseases with comorbidities or associated risk factors may impair the function of regenerative cells and the regenerative microenvironment. Following this consideration, the vasculogenic conditioning culture (VCC) method was developed to boost the regenerative microenvironment to achieve regeneration-associated cells (RACs), which contain vasculogenic endothelial progenitor cells (EPCs) and anti-inflammatory/anti-immunity cells. Preclinical and clinical studies demonstrate that RAC transplantation is a safe and convenient cell population for promoting ischemic tissue recovery based on its strong vasculogenicity and functionality. The outputs of the scientific reports reviewed in the present study shed light on the fact that RAC transplantation is efficient in curing various diseases. Here, we compactly highlight the universal features of RACs and the latest progress in their translation toward clinics.

Effect of Repetitive Intra-Arterial Infusion of Bone Marrow

SDF1 gradient associates with the distribution of c-Kit+ cardiac cells

Interleukin-10 Deficiency Alters Endothelial Progenitor Cell

Infarct volumes at day 21 following various cell transplantation

Localization of administered mesenchymal stem cells (MSCs) and

Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat

QQc restores tubular formation of diabetic progenitor cells. A

Human peripheral blood mononuclear cells enriched in endothelial

Therapeutic application of regeneration-associated cells: a novel

Mesenchymal stem cells: environmentally responsive therapeutics

Mehdi Hassanpour on LinkedIn: I'm so pleased to share that I'm

Cell therapy trials for heart regeneration — lessons learned and

Chronological development of EPC-based cell therapies. Since EPCs